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Introduction: We hypothesized that cells present in normal tissue that bear cancer stem cell markers may
represent a cancer cell of origin or a microenvironment primed for tumor development, and that their presence
may correlate with the clinically defined subtypes of breast cancer that show increased tumorigenicity and stem
cell features.
Methods: Normal tissues sampled at least 5 cm from primary tumors (normal adjacent tissue) were obtained from
61 chemotherapy-naive patients with breast cancer treated with mastectomy. Samples were stained simultaneously
with immunofluorescence for CD44/CD49f/CD133/2 stem cell markers. We assessed the association between
CD44+CD49f+CD133/2+ staining in normal adjacent tissue and breast cancer receptor subtype (defined by the
expression of the estrogen (ER), progesterone (PR), or human epidermal growth factor-2 (Her2) receptors). We also
examined the correlation between CD44+CD49f+CD133/2+ immunofluorescence and each of two previously
published gene signatures, one derived from stem-cell enriched tissue and one from BRCA mutated tissue
expected to have defective DNA repair.
Results: Patients with triple negative breast cancer (ER–/PR–/HER2–) expressed CD44+CD49f+CD133/2+ in 9 of 9
normal adjacent tissue samples compared with 7 of 52 ER+ and/or Her2+ tumors (P < 0.001). Further, expression of
CD44+CD49f+CD133/2+ by normal adjacent tissue correlated positively with a stem cell-derived tumorigenic
signature (P <0.001) and inversely with a defective DNA-repair signature (P <0.001).
Conclusion: Normal cells bearing cancer stem cell markers are associated with the triple negative receptor subtype
of breast cancer. This study suggests stem cell staining and gene expression signatures from normal breast tissues
represent novel tissue-based risk biomarkers for triple negative breast cancer. Validation of these results in
additional studies of normal tissue from cancer-free women could lay the foundation for future targeted triple
negative breast cancer prevention strategies.* Correspondence: jcchang@tmhs.org
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Breast cancer is a heterogeneous disease consisting of
various receptor subtypes that have different treatment
options and long-term survival probabilities. Clinically
defined subtypes have been described on the basis of
immunohistochemical expression of the estrogen receptor
(ER), progesterone receptor (PR), and human epidermal
growth factor receptor-2 (Her2). The so-called triple-
negative subtype (ER–/PR–/Her2–) accounts for fewer
than 20% of breast cancer cases. However, because of
its poor prognosis and lack of treatment options triple-
negative disease is responsible for a disproportionate
number of breast cancer deaths [1]. Although chemo-
prevention strategies with tamoxifen and exemestane
are available to suppress or prevent the development of
ER-positive tumors, no chemoprevention measures are
available for triple-negative breast cancer [2].
Increasing evidence from recent clinical studies supports
the hypothesis that breast tumors contain a subpopulation
of cells with distinct properties similar to stem cells
(reviewed in [3]). The various combinations of surface
markers used to identify breast cancer stem cells include
CD44+/CD24-/low, aldehyde dehydrogenase (ALDH1) activ-
ity (identified by the Aldefluor assay), and more recently
CD44+/CD49f+/CD133/2+; all define subpopulations of
cells that have been shown in limiting dilution xenograft
transplantation assays to have increased tumorigenic poten-
tial [4-7]. Differences in results obtained from experimental
studies to date suggest that these markers may differ
depending on tumor type.
We previously generated a breast cancer stem-cell
signature that comprised 493 differentially expressed
genes, patterns of which were present in a tumorigenic
subpopulation of cells identified by using putative stem-
cell markers [8]. The breast cancer stem cell signature was
generated by combining two subpopulations of 36 breast
tumors sorted for CD44+/CD24-/low markers and the
cells that were able to form mammospheres on low-
attachment plates. The tumors collected represented all
subtypes of breast cancer (18 luminal A/B, 13 basal-like,
and 5 Her2 cancers). Comparative gene expression profiling
was performed on these populations and compared to the
bulk of the tumor (non-CD44+/CD24-/low cells) and ana-
lyzed for significant overlap between the gene expression
patterns. When compared with breast tumors, this sig-
nature was found to correlate most closely with gene
expression patterns in tumors identified as claudin-low
molecular subtype. Functionally, stem cells are associated
with enhanced DNA repair, which may explain their
resistance to both chemotherapy and radiation [9,10].
We previously identified a defective DNA damage repair
signature based on published BRCA signatures with a
subset of the 69 most differentially expressed genes [11].
This signature represents a BRCA-like phenotype expectedto be associated with defective DNA damage repair;
clinically, it has been associated with poor response to
anthracyclines [11].
Triple-negative breast cancer and the epidemiologic
factors associated with it are different from those of other
breast cancer subtypes [12-14]. Millikan et al. observed in
the Carolina Breast Cancer Study that African American
ethnicity, higher numbers of pregnancies, younger age at
full-term pregnancy, and shorter duration of breastfeeding
were associated with a higher risk of triple-negative breast
cancer [14]. A more recent study by Rosenberg’s’ group
found a similar association with reproductive risk factors
in a cohort of African American women [15]. Full-term
pregnancy followed by little or no breastfeeding has been
proposed to lead to the retention of the normal stem cell
pool intended to transiently expand to support lactation and
which is speculated to contract with extended breastfeeding.
This could preferentially lead to the development of
triple-negative breast cancer, which is most closely asso-
ciated with a cancer stem-cell phenotype [16-20].
The idea that some breast cancers develop from stem
cells is controversial and highly dependent on the subtype
of breast cancer. In this study, we investigated normal tis-
sue samples adjacent to breast tumors in women with a
variety of subtypes of breast cancer. We hypothesized that
the adjacent normal breast tissue in women with triple-
negative breast cancer may contain increased numbers of
cells bearing cancer stem-cell markers.
Methods
Patient samples
We randomly identified 61 patient samples from a tissue
bank of normal breast tissue obtained from mastectomy
specimens from women undergoing surgery for breast
cancer from July 2005 through July 2007. These biopsy
specimens had been obtained at least 5 cm away from
the tumor. Tissue samples from 11 women who under-
went prophylactic contralateral mastectomy were also
analyzed. The normal adjacent breast tissue had been
collected in optimum cutting temperature cryoembedding
medium and formalin and then embedded in paraffin.
A section of each specimen was verified by two inde-
pendent pathologists, who used hematoxylin and eosin
staining according to standard protocols. Only samples
containing normal breast tissue with at least 10 to 20%
epithelial content, with associated 60% tumor cellular-
ity were selected and used for both staining and as-
sessment of gene expression. The investigators were
blinded to patient identity and the clinicopathologic
features of the tumor for imaging and analysis. This
study was approved by the appropriate institutional
review board of The University of Texas MD Cancer
Center. All patients gave their written informed con-
sent prior to study inclusion.
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The methods for gene expression experiments have been
described previously [21]. Briefly, total RNA was isolated
using TRIzol (Invitrogen Corp., Carlsbad, CA, USA).
Samples were then passed over Qiagen RNeasy (Qiagen,
Valencia, CA, USA). After RNA recovery with a T7 pro-
moter primer, cDNA was synthesized and fluorescently
labeled, and the labeled cRNA samples were hybridized
onto an (Affymetrix, Santa Clara, CA) U133 Plus2
GeneChip, which contains approximately 34,000 genes,
according to the manufacturer’s recommended proce-
dures. The median amount of RNA extracted was 25 μg
(range 19 to 33 μg). The quality of the RNA was good, as
previously published, the percent call was high at be-
tween 40 and 50%, and the glyceraldehyde-3-phosphate
dehydrogenase (GADPH) ratio was below 1.0. dChip wasFigure 1 Stem cell cell surface markers were present in the triple neg
the estrogen receptor-positive (ER+) sample. (A) Normal adjacent tissue
green, CD133/2; blue, 4',6-diamidino-2-phenylindole (DAPI) and combined
tissue from a patient with ER+ disease, no combined cells CD44+/CD49f+/Cused to estimate expression values by using the perfect
match/mismatch (PM/MM) difference model and invari-
ant set normalization [21].
Immunohistochemical analysis
Approximately six different areas of epithelial cells from
each sample were scored, with each area consisting of
approximately 200 cells. Immunofluorescence staining
for CD44, CD49f, CD133/2, and 53BP1 was performed
according to previously published methods [7,22] with
the following antibodies: rabbit anti-CD44 (Abcam,
Cambridge, MA), rat anti-CD49f (BD Biosciences, San
Jose, California), mouse anti-CD133/2 (Miltenyi Biotech,
Auburn, CA), and rabbit anti-53BP1 rabbit polyclonal
(Novus Biologicals, Littleton, CO). All secondary anti-
bodies were purchased from (Invitrogen, Grand Island,ative normal adjacent tissues to a much greater extent than in
from a patient with triple-negative cancer: red, CD44; purple, CD49f;
CD44+/CD49f+/CD133/2+. Scale bar 25 μm (40×). (B) Normal adjacent
D133/2+. Scale bar 25 μm (40×).
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647, or anti-mouse Alexa Fluor 488. A positive score was
defined as more than 1% positive staining and a nega-
tive score was assigned for less than 1% positive cells.
Microscopy
Microscopic analysis was performed at 40× magnification
with a Leica TCS SP5 confocal microscope and a Leica LAS
AF to detect the expression of CD44, CD49f, and CD133/2.
Microscopic analysis was also done at 40× magnification
with an Olympus IX-81 DSU confocal microscope using 3I’s
(Slidebook Software (V5.0), Denver, CO) to quantify 53BP1.
Statistical methods
Frequency counts and summary statistics were calculated
for all clinical and epidemiologic data, and the variables were
compared between stem cell-positive and stem cell-negative
tissue samples. Associations between the tumorigenic
signature and stem cell staining were assessed by using
the Wilcoxon rank sum test. Given a previously defined
gene expression signature of interest (for example, for
tumorigenic cells or DNA damage response), we scored
each of the normal adjacent breast tissue expression
profiles for similarity to the signature pattern by using
our previously described t-score metric [8,23]. Briefly,
the gene signature t-score was defined as the two-sidedFigure 2 Gene expression patterns associated with tumorigenic cells
for the stem-cell markers CD44+/CD49f+/CD133/2+. On the basis of gen
score for similarity to a previously defined gene signature of tumorigenic c
signature (P <0.001, Wilcoxon rank sum test): black bar, normal adjacent tis
stem cell presence and triple-negative tumor subtype (P = 0.001), breastfeet-statistic comparing the average of the signature-high
genes with that of the signature-low genes within each
tumor (after first centering the log-transformed expression
values for the breast dataset on the median across samples).
As exploratory analyses, Kaplan-Meier curves were gen-
erated for the stem cell-positive and stem cell-negative
groups, and the log-rank test was used to determine sig-
nificant differences in survival times between the two
groups. Recurrence-free survival time was defined as the
time from the date of the initial diagnosis of breast cancer
to the date of distant or local recurrence, whichever came
first. Subjects who were alive and recurrence-free at the last
follow up were censored on that date. All P-values were
two-sided with α = 0.05, and all statistical analyses were
conducted using STATA 10.0 (College Station, TX, USA).
Graphs were generated using GraphPad Prism version 4.00
for Macintosh (GraphPad Software, San Diego, CA, USA;
www.graphpad.com).
Results
Increased prevalence of cancer stem-cell markers in the
normal adjacent tissue of patients with triple-negative
breast cancer
The presence of the cell surface markers CD44+/CD49f+/
CD133/2+ was significantly increased in normal adjacent
tissue associated with patients with triple-negative breastare manifested in normal breast samples with positive staining
e expression profiling, normal breast samples were each assigned a
ells. CD44+CD49f+CD133/2+ samples scored highly for the gene
sue. Analysis of epidemiologic factors revealed associations between
ding (P = 0.04) and recurrence (P = 0.01). *P <0.05.
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tumors combined (seven of fifty-two) (P <0.001); represen-
tative samples are shown in Figure 1 and Additional file 1.
The average number of fields positive in normal adja-
cent tissue with at least 1% positive staining was 60.5%
(range 20.0 to 100.0%). The average number (range) of
cells positive for CD44, CD49f, and CD133 in normal
adjacent tissue associated with triple-negative cancer was
66.0% (20.0 to 100.0%), 57.0% (20.0 to 80.0%), and 52.0%
(10.0 to 80.0%), with no significant differences between
the expression of the markers. In pairwise comparisons
between the tissues positive for CD44+/CD49f+/CD133/2+Figure 3 Lack of DNA damage found in stem cell-positive tissues. (A) In
DNA-repair signature (white bar); *P = 0.001. (B) 53BP1 staining in normal adja
(C) The presence of 53BP1 foci correlates significantly with the defective DNA
damage present; black bars, no DNA damage present; asterisks indicate a recu
closed circles indicate triple-negative breast cancer; closed squares indicate Cthere was no significant difference in the expression of
individual markers between the triple-negative and ER+
tissues. Staining prevalence and patterns in all cases where
a prophylactic contralateral mastectomy sample was avail-
able were similar to the staining on the paired ipsilateral
side, including the two samples from patients with triple-
negative disease (data not shown).
Tumorigenic signature in normal adjacent breast tissue
with positive staining for CD44+/CD49f+/CD133/2+
We scored the gene expression profiles of the normal
adjacent breast specimens for expression of a tumorigenicverse correlation between stem-cell signature (black bar) and defective
cent tissue. Green foci (arrows) indicate DNA damage, scale bar 50 μm.
repair signature (P <0.001, Wilcoxon rank sum test). White bars, DNA
rrence event (all events were within the cohort with negative scores);
D44+/CD49f+/CD133/2+.
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high signature manifestation and CD44+CD49f+CD133/2+
stem-cell staining (Figure 2, P <0.001). The nine normal
adjacent breast specimens from patients with triple-
negative breast cancer, which were all positive for CD44+
CD49f+CD133/2+ stem cell staining, also all exhibited high
tumorigenic signature patterns. In addition, all seven of
the normal adjacent tissues from women with ER+ breast
cancer that were positive for CD44+CD49f+CD133/2+ also
exhibited high tumorigenic signature patterns. These
data support the concept that the tissues identified by
immunofluorescence as positive for stem-cell markers
also exhibit a stem cell-like gene expression profile. In
normal adjacent tissue from women with ER+ breast
cancer, 15 out of 45 were positive for the stem cell-like gene
expression profile without expression of CD44+CD49f+
CD133/2+. The average tumorigenic signature score for
tissues stained positive for CD44+CD49f+CD133/2+ was
9.09 and the average for tissues stained negative was −3.04
(Figure 2, P <0.001, Wilcoxon rank sum test).
DNA damage and function
Tissues characterized for stem-cell marker staining and
gene expression were also characterized for the presence of
DNA damage as assessed by 53BP1 immunohistochemical
staining and the expression of a defective DNA repair
signature. Within the normal adjacent breast specimens,
the defective DNA damage signature patterns were
inversely related to the stem-cell signature patterns
(Figure 3A, P <0.001). All of the tissues were stained
with 53BP1 to validate the DNA damage signature with
a protein-based repair surrogate (Figure 3B). Significantly
positive defective DNA repair-gene expression was asso-
ciated with an abundance of DNA damage (53BP1 foci)
(Figure 3C). Interestingly, all of the clinical events (localFigure 4 Recurrence-free survival among all patients, grouped by ste
lines, stem cell-positive group. Recurrence-free survival was better among precurrence, distant metastasis, and death from cancer)
took place among women whose samples had a negative
defective DNA damage score.
Epidemiologic factors and survival analysis
Comparison of epidemiologic factors between patients with
stem-cell marker-positive or stem-cell marker-negative
normal adjacent tissue revealed that marker-positive tissue
was associated with never breastfeeding (P = 0.04) and
shorter breastfeeding duration per child (1.8 ± 2.9, 4.5 ± 6.1
months, P = 0.05) in the stem-cell marker-positive cohort
(Figure 2). Although this study was not powered to compare
recurrence-free survival between subgroups, the outcomes
did seem to be different for patients with tissue that stained
positively versus negatively for the presence of stem cells
(Figure 4) (P = 0.02). The risk of recurrence was higher in
those with stem cells present (hazard ratio = 6.11, 95% CI
1.12, 33.37), but there was no association between triple-
negative disease and breast cancer recurrence.
Discussion
We found that the normal adjacent tissue associated with
triple-negative breast cancer contains cells that express the
same cell-surface markers as do triple-negative breast
cancer stem cells and also shows global gene expression
that closely correlates with a previously published tumori-
genic cancer stem-cell signature. In addition, both a defect-
ive DNA-repair gene expression signature as well as 53BP1
staining indicated that normal adjacent tissue associated
with triple-negative breast cancer had enhanced DNA
repair compared with normal adjacent tissue from women
with ER+ or Her2+ breast cancer. Although correlative,
these findings are consistent with the hypothesis that
stem cells present in normal breast tissue that is patho-
logically without evidence of any tumor cells may bem cell-staining status. Dashed lines, stem cell-negative group; solid
atients with cells staining positive for stem-cell markers (P = 0.02).
Atkinson et al. Breast Cancer Research 2013, 15:R77 Page 7 of 9
http://breast-cancer-research.com/content/15/5/R77either the cell of origin for breast cancer or promote a
tumor-conducive microenvironment necessary for the
development of breast cancer.
Interestingly, the risk factors associated with the develop-
ment of triple-negative breast cancer are different from
those for breast cancer as a whole [24]. Several epidemio-
logic studies have shown that women with higher numbers
of pregnancies, younger age at full-term pregnancy, and
shorter duration of breastfeeding are at increased risk
for triple-negative breast cancer [14,15]. During pregnancy,
progenitor cells in the breast terminal ducts proliferate and
undergo terminal differentiation, apoptosis, or both, during
lactation and involution [16]. Although the biological
mechanism underlying this process is not well-understood,
investigations with various mouse models have demon-
strated that pregnancy and lactation affect the number and
differentiation status of breast stem cells [25-27]. In our
study, both the staining for stem cells and the associated
gene signature were disproportionately higher in normal
adjacent breast epithelium associated with triple-negative
breast cancer. Our results are consistent with our hypoth-
esis that breast epithelium from patients with triple-
negative disease contains more stem cells and that their
presence may be linked to reproductive factors. Consistent
with this hypothesis, we found that patients with stem
cells in the normal adjacent tissue were less likely to have
breastfed and had a shorter duration of breastfeeding.
These results raise interesting questions regarding the
prevention of triple-negative breast cancer. Future studies
will attempt to identify these cells in biopsies from patients
without breast cancer and to correlate these to the develop-
ment of breast cancer in high-risk cohorts.
The results from immunofluorescence staining for
stem-cell markers strongly support the hypothesis that
women with triple-negative breast cancer have more
stem cells present in their normal breast tissue than do
women with other types of cancer. Although the normal
epithelial hierarchy is a useful framework to understand the
cellular origins of the different subtypes of breast cancer,
these findings remain correlative until formally proven
by assessing the tumorigenic capability of these different
cell populations or their assessment in patients without tu-
mors. Helland et al. recently investigated gene expression
patterns in normal breast biopsy samples [28] and identified
a subset of women with tissues enriched with a claudin-low
signature. An alternative explanation for our findings
is that the presence of stem-cell markers as well as the
tumorigenic signature in the normal adjacent tissue reflect
the tumor’s influence on the adjacent normal tissue. How-
ever, the similar staining patterns and gene expression sig-
natures in the contralateral normal breasts of women who
underwent contralateral prophylactic mastectomy make
this less likely. If indeed the former is true then this also
suggest the location of the tumor may be random, giventhe wide spatial dispersal of stem cells found within the
normal breast tissue.
The results on the DNA-damage signature are consistent
with the stem cell hypothesis and have an interesting bearing
on ongoing studies of poly (adenosine diphosphate-ribose)
polymerase (PARP) inhibitors in triple-negative breast
cancer. An initial phase II clinical trial using iniparib, a
PARP inhibitor, with gemcitabine showed clinical benefit
and improvement in survival for women with metastatic
triple-negative breast cancer, but further studies have not
confirmed that PARP inhibitors provide a progression-free
survival benefit in triple-negative breast cancer [29]. The
mixed results from clinical trials suggest that a specific
subpopulation of patients may benefit from the PARP in-
hibitors, perhaps those patients with defective DNA repair
pathways. On the basis of our findings on the DNA-repair
signature, we estimate that only one of nine patients with
triple-negative disease may have defective DNA repair.
However, we acknowledge that this signature was derived
from triple-negative breast tumors, and the results and
interpretation are hypothesis-generating and should be
considered with caution.
Conclusion
To our knowledge this is the first report that stem cells are
enriched in the normal adjacent breast tissue of patients
with triple-negative breast cancer. The presence of stem
cells may be an important predictive marker for the risk
of developing triple-negative breast cancer. However,
temporality and functional studies are needed to deter-
mine a causal relationship between stem cells and the
incidence of breast cancer. Establishing the etiologic re-
lationships between tumor subtypes by using normal
epithelial subsets has profound implications for the de-
velopment of clinically useful diagnostic and prognostic
markers, as well as targeted therapies.
Additional file
Additional file 1: Figure S1. Stem-cell cell surface markers were
present in the triple-negative normal adjacent tissues to a much greater
extent than in the estrogen receptor-positive (ER+) sample. (A) Normal
adjacent tissue from patients with triple-negative cancer; arrows indicate
areas positive for CD44+/CD49f+/CD133/2+(40×). (B) Normal adjacent
tissue from patients with ER+ disease. Scale bar 50 μm; red, CD4; purple,
CD49f; green, CD133/2; blue, 4',6-diamidino-2-phenylindole (DAPI), and
combined CD44+/CD49f+/CD133/2+.
Abbreviations
ALDH1: Aldehyde dehydrogenase; BRCA1: Breast cancer 1 gene; DAPI:
4',6-diamidino-2-phenylindole; ER: Estrogen receptor; GADPH: Glyceraldehyde-3-
phosphate dehydrogenase; Her2: Human epidermal growth factor-2; PARP: Poly
(adenosine diphosphate-ribose) polymerase; PM/MM: Perfect match/mismatch;
PR: Progesterone receptor.
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